Frontage Holdings Corp. · HKEX:1521
Frontage — Investor Presentation (May 2017)
29 slides from Frontage's investor presentation, May 2017

Slide 1: Laboratory and Clinical Services
Laboratory and Clinical Services Biometrics Clinical CMC DMPK Bioanalytical 1

Slide 2: 15+ Years of Strong Growth
15+ Years of Strong Growth March 2015 - Acquired Sister CDMO 200 200 201 BDM with 201 company 4 Opened Expanded & 4 Data 5 Frontida Company Shanghai, 8 Relocated HQ to Management acquired in Founded by Dr. China office Exton, PA and Biostats Philadelphia, Song Li Services PA Opened Began Phase Strat

Slide 3: Locations around the globe
Locations around the globe 160-Bed Facility • Early Phase USA Clinical • Secaucus, NJ CHINA Bioanalytical Data Services Management • Shanghai, Suzhou Headquarters and Biometrics Bioanalytical, DMPK • BDM CMC Services • Exton, PA • Suzhou Consulting • Somerset, NJ Hospital-Based CMC Services • Exton,

Slide 4: Service Offerings
Service Offerings Laboratory Services Clinical Services DMPK BIOANALYTICAL CMC CLINICAL BIOMETRICS Insight. Expertise. Quality. Agility. Intelligence. It’s how your candidates It’s how you get from the It’s how you get from It’s what gets you from the It’s how you turn data become real contenders. m

Slide 5: US FDA Facility Inspections (2004-2016)
US FDA Facility Inspections (2004- 2016) # Facility Inspection Service Area (Location) FEI # Inspection/s Year/s BIO-US/ CMC-US (HQ, Exton, PA) 3003542039 10/2 2004-2016 CMC-US (Exton, PA) 3006799640 7 2006-2016 CRC-US (Hackensack, NJ) 3005134380 4 2009-2014 CRC-US (Secaucus, NJ) 3011480129 1 2016 B

Slide 6: Other Regulatory Inspections (2009-2016)
Other Regulatory Inspections (2009-2016) # of Inspection Service Area (Location) Agency Inspection/s Year/s BIO-DMPK-US (HQ Exton, PA) US EPA 1 2015 CMC-US (Exton, PA) Health Canada 1 2016 Clinical Investigator (CI) - US FDA 4 2009-2015 US/China BIO-CH (Shanghai, China) WHO 1 2013 CRO-CH (Beijing, C

Slide 7: Why Frontage?
Why Frontage? Technical Highest Flexibility Innovation With 70% of our Expertise We have an Standards We value agile Our $40M facility scientists holding unparalleled project investment and advanced degrees compliance and management, & 450 FTE in USA & and our depth & quality track a commitment to C

Slide 8: Laboratory Services: DMPK
Laboratory Services DMPK 8

Slide 9: Drug Discovery & Development
Drug Discovery & Development Commerci Lead Registrati Hits to Pre- al Launch Optimizat on (IND) Phase II Phase III Leads clinical (NDA) ion Phase I Phase IV DMPK Services – from Discovery to NDA Discovery Studies Preclinical Clinical Studies • Metabolite • PK/PD Studies Studies ID/Profiling in • MIS

Slide 10: DMPK Overview
DMPK Overview One-stop Experienced Varied Client Shop Staff Base • Iin vitro/in vivo • 25+ employees; • Pharmaceuticals DMPK support for cross-trained; avg. • Universities discovery and experience 10-15 • NIH development years • Government • EPA, GLP, & non- • Ability to provide agencies GLP studies

Slide 11: Laboratory Services: Bioanalytical
Laboratory Services Bioanalytical 11

Slide 12: Global Bioanalytical Operations
Global Bioanalytical Operations • ~ 130 Staff in • 1,400+ • Mostly Proprietary Assays • 80+ Available USA and China Mostly Proprietary Assays • 80,000+ Sq. Assays • 200,000+ • Ongoing Ft. • 500,000+ Samples (Annual Capacity) Customized Assays and Therapeutic • Majority of Samples (Annual Focus Scien

Slide 13: Small Molecule Capabilities
Small Molecule Capabilities Expertise in New Expertise in Method Sample Sample Collection Labile Compound Development, Analysis Procedure Method Transfer & • Nonclinical Development Development Validation • DBS sampling • Enzymatic toxicokinetic/phar • Micro-sampling instability macokinetic techniqu

Slide 14: Biologics Capabilities
Biologics Capabilities Biologics Molecule Types Monoclonal Antibodies, Antibody Drug Conjugates, Oligonucleotides, Peptides, Biomarkers Ligand Binding Assays Analysis Method LC-MS/MS ELISA & ECL PK/TK – Pharmacokinetics Assays Immunogenicity Assays Techniques Anti-Drug Antibody Assays, Neutralizing

Slide 15: Laboratory Services
FRONTAGE YOUR DRUG DEVELOPMENT PARTNER a= a) aa aes Laboratory Services

Slide 16: CMC Teams
CMC Teams Organic Synthesis API Product Development Analytical Testing CTM Manufacturing 16

Slide 17: Product Development and CTM Manufacturing
Product Development and CTM Manufacturing Work with > 170 clients for > 170 compounds and >370 GMP batches ANDA: Reverse IND: Formulation Engineering/Formula Development tion Dev/Tech Consumer Products: /CTM/IND (OSD, Transfer OTC reformulation Topical, Sterile) • Formulation and Process Development

Slide 18: Analytical Services
Analytical Services Method Development, Validation and Transfer • Developed and/or validated over 1,350 methods (~100 methods/year) • HPLC (20), UPLC (22), GC (2), GC/MS, IC, HPLC/MS, UPLC/MS, ICP/OES, ICP/MS • Dissolution (16) • Diffusion IVRT and Skin Permeation IVPT testing (48 Franz cells) Unkno

Slide 19: GMP Sample Stability Testing
GMP Sample Stability Testing FDA-Inspected Labs for commercial stability study Over 4,500 cubic feet of storage (6 walk-in 8’x8’ rooms; 6 reach-in chambers) Typical ICH storage conditions & WHO (Zone IVb hot/higher humidity) • 25oC/60%RH, 30oC/65%RH, 40oC/75%RH, 30oC/75%RH Low Humidity for Semi Perm

Slide 20: Clinical Services
Clinical Services Clinical 20

Slide 21: Clinical Research Facility – Secaucus, NJ
Clinical Research Facility – Secaucus, NJ • State of the Art Facility • Less than 5 miles from NYC • ½ mile from local medical center • Near major airports and mass transit • 36,000 sq. ft. 160 Beds • Multiple units can be combined to accommodate any size study • Telemetry Unit • Safe drug handling

Slide 22: Clinical Research at A Glance
Clinical Research at A Glance Seven Early Data Phase Clinical Management Facilities in the and Biometrics U.S. and China EDC support & Experience with novel statistical compounds and programming, access to a diverse including e-Submission range of subject and CDISC support populations and patients C

Slide 23: Diverse Study Experience
Diverse Study Experience Study Types • First-in-Human Over 20 years of experience in • Single and Multiple Dose Escalation conducting early phase clinical • Bioequivalence • Absolute and Relative Bioavailability trials • Drug-drug Interaction Studies • Food and Alcohol Effect Studies Completed in La

Slide 24: Clinical Services: Biometrics
Clinical Services Biometrics 24

Slide 25: Biometrics Services to Rapidly Compile the Clinical Study Report
Biometrics Services to Rapidly Compile the Clinical Study Report Biostatistics Data Medical and Regulatory Management Writing Programming • Rigorous • Biostatistics • Pharmacokin • Insight into SOPs for Consultation etic (PK) Clinical Regulatory and Analyses Analysis led Development Standards by Sta

Slide 26: Snapshot of China Operations
Snapshot of China Operations Clinical CMC Bioanalytical 26

Slide 27: Frontage China Operations
Frontage China Operations Labs in function from Headquartered in 2006 (the first global Zhangjiang Hi-Tech standard GLP lab in Park, Shanghai China) Director and above levels are trained Multiple times abroad and have successfully passed multiple years FDA and WHO site working experience inspections

Slide 28: Frontage China Services
Frontage China Services Bioanalytical CMC/CTM Clinical • >26,000 sqf • >30,000 sqf • Hospital-based facilities located in facilities located in early phase clinical Shanghai and Suzhou centers in different Suzhou regions • >40 Scientists; • >50 Scientists; >70% have • >250 beds phase I >70% have adv

Slide 29: Global Headquarter Locations
Global Headquarter Locations U.S. Headquarters China Headquarters 29
Source: Internet Archive copy of frontagelab.com





